EGFR
Clinical trials for EGFR explained in plain language.
Never miss a new study
Get alerted when new EGFR trials appear
Sign up with your email to follow new studies for EGFR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill plus chemo aims to stop lung cancer comeback in patients with rare mutations
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug zipalertinib to standard chemotherapy can delay or prevent lung cancer from returning in people with early-stage non-small cell lung cancer (stages IB to IIIA) who have uncommon EGFR mutations. After complete tumor removal…
Matched conditions: EGFR
Phase: PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill takes on tough cancers: first human trial begins
Disease control OngoingThis early-phase study tests a new oral drug called TT125-802 in 50 adults with advanced solid tumors (like lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. It is a fi…
Matched conditions: EGFR
Phase: PHASE1 • Sponsor: TOLREMO therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Lung cancer clue: could a DNA glitch open door to new treatments?
Knowledge-focused OngoingThis study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…
Matched conditions: EGFR
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Smartwatch and app aim to track lung cancer symptoms in real time
Knowledge-focused OngoingThis study tests whether a remote monitoring system—including a smartphone app, a Fitbit, and a smart pill cap—can effectively track symptoms and side effects in 30 lung cancer patients taking oral targeted therapy. Participants will use the system for up to 24 weeks, and the goa…
Matched conditions: EGFR
Phase: NA • Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC